APA (7th ed.) Citation

Qi, W., Wang, X., Li, C., Li, S., Li, H., Xu, F., . . . Li, H. (2023, June). Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort. Thoracic Cancer.

Chicago Style (17th ed.) Citation

Qi, Wei‐Xiang, Xiaoyan Wang, Chengqiang Li, Shuyan Li, Huan Li, Feifei Xu, Jiayi Chen, Shengguang Zhao, and Hecheng Li. "Pretreatment Absolute Lymphocyte Count Is an Independent Predictor for Survival Outcomes for Esophageal Squamous Cell Carcinoma Patients Treated with Neoadjuvant Chemoradiotherapy and Pembrolizumab: An Analysis from a Prospective Cohort." Thoracic Cancer Jun. 2023.

MLA (9th ed.) Citation

Qi, Wei‐Xiang, et al. "Pretreatment Absolute Lymphocyte Count Is an Independent Predictor for Survival Outcomes for Esophageal Squamous Cell Carcinoma Patients Treated with Neoadjuvant Chemoradiotherapy and Pembrolizumab: An Analysis from a Prospective Cohort." Thoracic Cancer, Jun. 2023.